The Food and Drug Administration has approved a blood test called Shield, developed by Guardant Health, to screen for colon cancer. The test, while not meant to replace colonoscopies, is seen as a potential way to increase screening rates for the second-highest cause of cancer death in the United States. Shield has previously been available for a cost of $895, but with FDA approval, Medicare and private insurance companies are likely to cover the cost, making it more accessible for patients. However, positive test results would still require a colonoscopy to confirm a diagnosis.
Research has shown that Shield is 83% effective in finding colorectal cancers, but it is more effective in detecting later-stage cancers. The test would need to be repeated at least every three years, starting at age 45, the same age recommended for colorectal screening. Despite the availability of effective screening methods such as colonoscopy and blood tests, screening rates for colon cancer remain low, with many people not getting screened as recommended.
While colonoscopy is considered the most accurate way to detect colon cancer, many people are hesitant to undergo the procedure due to time constraints, discomfort, and the need for pre-procedure preparations. The availability of blood tests like Shield may help increase screening rates by providing a less invasive option for those who are reluctant to undergo a colonoscopy. The hope is that increased screening will lead to early detection and prevention of colon cancer, ultimately reducing mortality rates associated with the disease.
Photo credit
www.nbcnews.com
